Q-omics provides the consensus-scored MARK2P13 profile across patient tissues and cancer cell-line models. MARK2P13 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MARK2P13 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, MARK2P13 RNA expression shows 6,069 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where MARK2P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARK2P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARK2P13 survival associations across molecular data types. MARK2P13 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARK2P13 RNA expression–survival associations across cancer types. High MARK2P13 expression shows unfavorable associations in KIRC, ACC, THYM, TGCT and LUAD, but favorable associations in LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MARK2P13 RNA expression.
This table summarizes MARK2P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MARK2P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARK2P13 shows lower tumor expression in BRCA, ESCA and THCA and higher tumor expression in KICH and HNSC. The BRCA box plot shows higher MARK2P13 RNA expression in normal versus tumor tissue (log2 FC = −0.013, t-test p = .011).
This table shows molecular features associated with MARK2P13 in patient tissues and cancer cell lines. In patient samples, MARK2P13 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
